Targeting the Microbiome to Overcome Resistance

Rebecca C Simpson¹, Erin Shanahan², Richard A Scolyer³, Georgina V Long⁴

Affiliations

¹ Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia.
² Charles Perkins Centre, The University of Sydney, Sydney, Australia; School of Life and Environmental Science, Faculty of Science, The University of Sydney, Australia.
³ Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, Australia.
⁴ Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia. Electronic address: georgina.long@sydney.edu.au.

PMID: 33561397
DOI: 10.1016/j.ccell.2021.01.016

Free article

Comment

Targeting the Microbiome to Overcome Resistance

Rebecca C Simpson et al. Cancer Cell. 2021.

Free article

. 2021 Feb 8;39(2):151-153.

doi: 10.1016/j.ccell.2021.01.016.

Authors

Rebecca C Simpson¹, Erin Shanahan², Richard A Scolyer³, Georgina V Long⁴

Affiliations

¹ Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia.
² Charles Perkins Centre, The University of Sydney, Sydney, Australia; School of Life and Environmental Science, Faculty of Science, The University of Sydney, Australia.
³ Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, Australia.
⁴ Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia. Electronic address: georgina.long@sydney.edu.au.

PMID: 33561397
DOI: 10.1016/j.ccell.2021.01.016

Abstract

Immune checkpoint inhibition has revolutionized the treatment of many cancers, including melanoma. However, primary and acquired resistance remain key challenges for the field. Promising results from a phase I clinical trial recently published in Science highlight the potential of modulating the microbiome via fecal transplant to overcome resistance to immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Declarations of Interests G.V.L. is a consultant advisor for Aduro Biotech Inc., Amgen Inc., Array Biopharma Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Hexel AG, Highlight Therapeutics S.L., Merck Sharpe & Dohme, Novartis Pharma AG, Pierre Fabre, QBiotics Group Limited, Regeneron Pharmaceuticals Inc, SkylineDX B.V., and Specialised Therapeutics Australia Pty Ltd. R.A.S. has received fees for professional services from Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, and GlaxoSmithKline.

Comment on

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B. Baruch EN, et al. Science. 2021 Feb 5;371(6529):602-609. doi: 10.1126/science.abb5920. Epub 2020 Dec 10. Science. 2021. PMID: 33303685 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Targeting the Microbiome to Overcome Resistance

Affiliations

Targeting the Microbiome to Overcome Resistance

Authors

Affiliations

Abstract

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical